Kenvue (NYSE:KVUE) General Counsel Matthew Orlando Sells 38,491 Shares

Kenvue Inc. (NYSE:KVUE) General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Kenvue Trading Up 1.7%

NYSE:KVUE opened at $17.47 on Wednesday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $24.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.68. The stock has a market capitalization of $33.54 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 1.30 and a beta of 0.55. The business’s 50-day simple moving average is $17.55 and its 200-day simple moving average is $17.29.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the previous year, the business posted $0.24 EPS. Kenvue’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date is Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Finally, Canaccord Genuity Group lifted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.33.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. NBT Bank N A NY increased its position in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC increased its holdings in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. increased its holdings in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue during the 4th quarter worth approximately $26,000. Finally, MV Capital Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.